Subcutaneous Infusion Therapies for Parkinson's: Expert Insights & Patient Benefits

An article in the European Medical Journal, published on March 17, 2026, compiles expert perspectives on the crucial role of subcutaneous (SC) infusion therapies in managing Parkinson's disease (PD). This discussion aims to address knowledge gaps and disseminate best practices within the neurology community, especially for patients experiencing motor fluctuations and dyskinesia not adequately controlled by oral medications. Parkinson's disease is a progressive neurodegenerative disorder characterized by a gradual loss of dopamine-producing neurons, leading to motor and non-motor symptoms. While levodopa is the gold standard for treatment, long-term use frequently results in motor fluctuations and dyskinesia, commonly referred to as 'OFF' (symptom return) and 'ON' (symptom improvement) periods. These fluctuations can significantly impair a patient's quality of life. Subcutaneous infusion therapies represent a significant advancement in device-assisted treatments for advanced PD. Unlike oral medications, which can be affected by gastrointestinal dysfunction—a common feature in PD—SC infusions deliver medication directly into the subcutaneous tissue, ensuring continuous and predictable drug release. This continuous dopaminergic stimulation helps avoid the peaks and troughs associated with intermittent oral dosing, leading to more stable symptom control. Key SC infusion therapies discussed include continuous subcutaneous apomorphine infusion (CSAI) and levodopa-based formulations like foslevodopa/foscarbidopa (e.g., Vyalev/Produodopa). Apomorphine, a dopamine agonist, has been used clinically for decades, with studies like the TOLEDO trial demonstrating significant reductions in 'OFF' time and increases in 'ON' time without troublesome dyskinesia. Foslevodopa/foscarbidopa is the first and currently the only approved levodopa-based SC formulation, showing similar efficacy in managing motor fluctuations. The benefits of SC infusion therapies are numerous. They are less invasive than surgical alternatives such as Deep Brain Stimulation (DBS) or intrajejunal levodopa/carbidopa enteral suspension (CLES), which require surgical tube placement. This non-invasive nature means SC infusions can be initiated quickly and are reversible; if a patient does not tolerate the treatment, they can discontinue it and still be candidates for other therapies like DBS. Clinical trials have shown that SC infusion can reduce daily 'OFF' time by nearly two hours and improve health-related quality of life and sleep scores. They can also serve as a 'bridging therapy' for patients awaiting DBS. Despite the significant advantages, SC infusion therapies come with challenges. The most common adverse events are local skin reactions at the infusion site, though these are generally manageable with appropriate care. Other side effects, such as somnolence and hallucinations, have been noted, sometimes leading to discontinuation. Moreover, the continuous nature of the therapy requires daily management and skin care from the patient or caregiver, which some patients might find burdensome compared to a surgically implanted device like DBS. Cost and availability are also major concerns, particularly in regions outside of Western countries, highlighting a global need for these accessible therapies. Compared to other advanced therapies, SC infusions offer a valuable middle ground. While DBS is highly effective in controlling erratic responses to levodopa and dyskinesias, it is a surgical procedure with associated risks. Levodopa/carbidopa intestinal gel (LCIG) also provides continuous delivery but requires a surgically placed intestinal tube. SC infusions bypass the need for surgery, making them an attractive option for patients who may not be suitable for or prefer to defer surgical interventions. For an Indian audience, this news is highly relevant. India faces a substantial burden of Parkinson's disease, with an estimated 771,000 patients in 2019 and a concerning trend of early-onset PD. While Deep Brain Stimulation (DBS) and advanced medical management are available in India at world-class hospitals, the cost can be a barrier. The less invasive nature of SC infusions, potentially offering a more accessible and adaptable treatment option, could significantly improve the quality of life for many Indian patients. Research in India is also exploring innovative drug delivery systems, such as nanoformulations for enhanced Parkinson's treatment, showing a commitment to advancing care locally. In conclusion, expert consensus underlines the significant benefits of subcutaneous infusion therapies in providing continuous, consistent symptom control for advanced Parkinson's disease, offering a less invasive yet effective alternative to traditional oral medications and more complex surgical interventions. Ongoing efforts focus on optimizing patient selection, managing side effects, and improving global access to these vital treatments.

Frequently Asked Questions

Read Full Story on Quick Digest